# Wuhan Wei Ke Medical Technology Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/wuhan-wei-ke-medical-technology-co

- Industry: Healthcare
- Headquarters: Wuhan, China
- Website: www.vickor.com.cn
- Latest round: Series B (Dec 16, 2021)
- Investors on record: 4

## About

Based in Wuhan, China, and established in 2018, Wuhan Wei Ke Medical Technology Co., Ltd is a medical company that focuses on researching and developing the therapies of structural heart disease. The company has completed 4 rounds of funding as of 2021. The company has applied for 35 patents, including 29 invention patents, 5 utility model patents, and 1 PCT patent. As of 2021, the company has 3,000 square meters of office buildings, a shared industry incubation platform with 10,000 square meters of GMP workshops, and 10,000-level laminar flow clean workshops.

The company's main business is research and development, technical services, production, and sales of three types of medical devices. The company's self-developed products include atrial shunt, cardiac occluder delivery system, nanomembrane patent foramen ovale occluder, and atrial septal puncture system.

The company plan to use the series B funding to promote the R&D and innovation of the company's multiple minimally invasive interventional products, and accelerate the process of product registration and withdrawal.

## Funding rounds

- Series B, Dec 16, 2021 — Hong Shan, Sharewin Investment
- Series A, Nov 25, 2020 — Sharewin Investment, Sunland Capital
- Series A, Jan 31, 2019 — Proxima Ventures

## Investors

- Proxima Ventures (https://capitalatlas.ai/funds/proxima-ventures) — Series A
- Sharewin Investment (https://capitalatlas.ai/funds/sharewin-investment) — Series A, Series B
- Sunland Capital — Series A
- Hong Shan — Series B